

SPECTRE - Combined suppression of cholesterol bioavailability and androgen deprivation therapy to treat castration resistant prostate cancer

Submission date 16/02/2016	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/02/2016	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 16/05/2024	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-using-a-drug-with-hormone-therapy-to-stop-prostate-cancer-from-spreading-spectre>

Contact information

Type(s)

Public

Contact name

Mrs Laura Alexander

Contact details

CRUK Clinical Trials Unit
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow
United Kingdom
G12 0YN
0141 301 7212
laura.alexander@glasgow.ac.uk

Additional identifiers

EudraCT/CTIS number

2015-003720-32

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

SPECTRE2015

Study information

Scientific Title

SPECTRE - Combined suppression of cholesterol bioavailability and androgen deprivation therapy to treat castration resistant prostate cancer: an interventional study

Acronym

SPECTRE

Study objectives

SPECTRE will establish whether inhibition of cholesterol biosynthesis in patients with ongoing ADT will suppress castration-resistant prostate cancer via a reduction in androgen mediated signalling.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Single-centre single-arm Phase II interventional study

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet.

Health condition(s) or problem(s) studied

Castration-resistant prostate cancer

Interventions

All eligible patients will receive a statin (Atorvastatin) to take orally for a 6 week period. Patients will be asked to attend the clinic once a week for 7 weeks, during the course of the trial. After completion of the trial medicine patients will attend for a further clinic visit, four weeks later. During each clinic visit, patients will be checked to ensure they are well, any side effects will be monitored and a blood test will be performed. Patients will also be asked to provide consent for additional blood samples at each study visit. These samples will be analysed in order to develop highly specific tests that will track the status of prostate cancer. Patients may also be requested to provide consent for two biopsy samples of their tumour; one before starting the trial medication, and another 5-7 weeks later. Biopsy samples will not be required from all patients taking part in the study.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Atorvastatin

Primary outcome measure

Achievement of $\geq 50\%$ drop from baseline in PSA levels at any time over the 6-week period of statins treatment (PSA response). The proportion of patients achieving PSA response rate will be presented together with an 80% confidence interval computed using the Clopper-Pearson approach.

Secondary outcome measures

1. Maximum percentage drop in PSA, determined for each patient and presented in a waterfall plot.
2. Change in levels of a number of biomarkers (circulating and tissue) following treatment with trial agent, including circulating cell-free tumour DNA (ctDNA), gene expression and other markers such as CTCs and exosomes

Overall study start date

01/07/2016

Completion date

20/12/2020

Eligibility

Key inclusion criteria

Current participant inclusion criteria as of 16/07/2018:

1. Proven adenocarcinoma of the prostate, defined as:
 - 1.1. Histological or cytological evidence of prostate cancer,
 - 1.2. PSA > 100 at time of diagnosis and presence of more than 4 bone metastases
2. Disease progression despite on-going castration therapy (either using LHRH analogue or prior surgical orchiectomy (with or without abiraterone or enzalutamide) as judged by rising serial PSA measurements. This will be based on a series of at least 3 readings each taken at least 7 days

apart. The 3rd reading must be ≥ 2 ng/ml. In the event where an intermediate reading is lower than a previous reading, then the patient will still be eligible (i.e. the 3 readings do not need to be consecutive). In patients who have received prior bicalutamide, flutamide or nilutamide, PSA progression must be proven after withdrawal of this drug.

3. Castrate levels of serum testosterone

4. Ongoing castration therapy (either LHRH analogue or prior orchiectomy, with or without abiraterone or enzalutamide). Please note, although the continuation of abiraterone or enzalutamide may be permitted, this must firstly be discussed with the chief investigator for approval, prior to study entry.

5. No therapy with statins or other cholesterol-lowering drug during a 28 day period prior to initiation of trial medication.

6. Male aged 18 or over

7. Life expectancy greater than 6 months

8. Adequate hepatic, bone marrow, coagulation and renal function as defined by the following criteria:

8.1. Haemoglobin ≥ 9.0 g/dL

8.2. Platelets $\geq 100 \times 10^9/L$

8.3. Creatinine

8.4. Hepatic function: total bilirubin $\leq 2 \times ULN$; ALT and AST $\leq 3 \times ULN$

8.5. Creatine kinase $\leq 5 \times ULN$

8.6. Prothrombin time $\leq 1.5 \times ULN$; APTT $\leq 1.5 \times ULN$

9. Willingness to comply with scheduled visits, medication plans and laboratory tests and other trial procedures

10. Ability to swallow oral medications

11. Willing to undergo two biopsies for research purposes with a lesion (either primary or secondary) amenable to biopsy

Previous participant inclusion criteria:

1. Histologically proven adenocarcinoma of the prostate (patients may or may not have evidence of metastatic disease)

2. Disease progression despite on-going castration therapy (either using LHRH analogue or prior surgical orchiectomy) as judged by rising serial PSA measurements: This will be based on a series of at least 3 readings each taken at least 7 days apart. The 3rd reading must be ≥ 2 ng/ml. In the event where an intermediate reading is lower than a previous reading, then the patient will still be eligible (i.e. the 3 readings do not need to be consecutive). In patients who have received prior bicalutamide, flutamide or nilutamide, PSA progression must be proven after withdrawal of this drug

3. Castrate levels of serum testosterone (<1.7 nmol/l)

4. Ongoing castration therapy (either LHRH analogue or prior orchiectomy)

5. No therapy with statins or other cholesterol-lowering drug during a 2-month period prior to initiation of trial medication

6. Male aged 18 or over

7. Life expectancy greater than 6 months

8. Adequate hepatic, bone marrow coagulation and renal function as defined by the following criteria:

8.1. Haemoglobin > 9.0 g/dL

8.2. Platelets $> 100 \times 10^9/L$

8.3. Creatinine $<2 \times ULN$

8.4. Hepatic function: total bilirubin $\leq 2 \times ULN$; ALT and AST $\leq 3 \times ULN$

8.5. Creatine kinase $\leq 5 \times ULN$

8.6. Fasting glucose ≤ 5.6 mmol/L

8.7. Prothrombin time $\leq 1.5 \times ULN$; APTT $\leq 1.5 \times ULN$

8.8. Platelets ≥ 100

9. Willingness to comply with scheduled visits, treatment plans and laboratory tests and other trial procedures

10. Ability to swallow oral medications

11. Willing to undergo two biopsies

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Male

Target number of participants

40

Total final enrolment

14

Key exclusion criteria

Current participant exclusion criteria as of 16/07/2018:

1. Uncontrolled hypertension (defined as systolic ≥ 170 mmHg and/or diastolic ≥ 100 mmHg, despite optimal therapy)
2. The requirement for strong opiates to control cancer related pain (codeine and tramadol are permitted)
3. NYHA class III or IV heart failure or Childs-Pugh liver failure class B or worse
4. Patients with symptomatic or radiographic disease progression (Note: Imaging studies will not be conducted specifically to meet this criterion but only if clinically indicated in accordance with standard of care)
5. Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the trial
6. History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol, or any psychological, familial, sociological or geographical consideration potentially hampering compliance with the trial protocol and follow up schedule.
7. Administration of any investigational drug within 28 days of receiving the first dose of trial medication
8. Major surgery within 28 days prior to trial registration
9. Active condition which affects drug absorption (e.g. prior gastrectomy or active peptic ulcer disease)
10. Planned change in systemic therapy for 6 weeks after study medication initiation
11. Planned requirement for radiotherapy or surgery for 6 weeks after study initiation
12. Prior hypersensitivity to atorvastatin or its constituents
13. Requirement for on-going anti-coagulant therapy (including heparins and warfarin)

Previous participant exclusion criteria:

1. Uncontrolled hypertension (defined as systolic ≥ 170 mmHg and/or diastolic ≥ 100 mmHg)

despite optimal therapy)

2. The requirement for strong opiates to control cancer related pain; codeine and tramadol are permitted
3. NYHA class III or IV heart failure or Childs-Pugh liver failure class B or worse
4. Patients with symptomatic or radiographic disease progression (Note: Imaging studies will not be conducted specifically to meet this criterion but only if clinically indicated in accordance with standard of care)
5. Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the trial
6. History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol, or any psychological, familial, sociological or geographical consideration potentially hampering compliance with the trial protocol and follow up schedule. Administration of any investigational drug within 28 days of receiving the first dose of trial treatment
7. Major surgery within 28 days prior to trial entry
8. Active condition which affects drug absorption (e.g. prior gastrectomy or active peptic ulcer disease)
9. Planned change in systemic therapy for 6 weeks after study initiation
10. Planned requirement for radiotherapy or surgery for 6 weeks after study initiation
11. Prior hypersensitivity to atorvastatin or its constituents
12. Requirement for on-going anti-coagulant therapy (including heparins and warfarin)

Date of first enrolment

20/12/2016

Date of final enrolment

20/12/2019

Locations

Countries of recruitment

Scotland

United Kingdom

Study participating centre

Beatson West of Scotland Cancer Centre

1053 Great Western Road

Glasgow

United Kingdom

G12 0YN

Sponsor information

Organisation

NHS Greater Glasgow and Clyde

Sponsor details

Research & Development
NHS Greater Glasgow & Clyde
West Glasgow Ambulatory Care Hospital
Dalnair Street
Glasgow
Scotland
United Kingdom
G3 8SW

Sponsor type

Hospital/treatment centre

Website

<http://www.nhsggc.org.uk/>

ROR

<https://ror.org/05kdz4d87>

Organisation

University of Glasgow

Sponsor details

Clinical Research & Development
West Glasgow Ambulatory Care Hospital
Dalnair Street
Glasgow
Scotland
United Kingdom
G3 8SW

Sponsor type

University/education

Funder(s)**Funder type**

Charity

Funder Name

Prostate Cancer UK

Alternative Name(s)

Prostate Cancer, Prostate Action, ProstateUK, prostatecanceruk

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan**Intention to publish date**

30/06/2021

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		16/08/2020	16/06/2022	No	No
Plain English results			16/05/2024	No	Yes